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Abstract
Background: Trypanosoma cruzi, the etiologic agent of Chagas Disease, is a major vector borne health problem in Latin
America and an emerging infectious disease in the United States.
Methods: We tested the efficacy of a multi-component DNA-prime/DNA-boost vaccine (TcVac1) against experimental T.
cruzi infection in a canine model. Dogs were immunized with antigen-encoding plasmids and cytokine adjuvants, and two
weeks after the last immunization, challenged with T. cruzi trypomastigotes. We measured antibody responses by ELISA and
haemagglutination assay, parasitemia and infectivity to triatomines by xenodiagnosis, and performed electrocardiography
and histology to assess myocardial damage and tissue pathology.
Results: Vaccination with TcVac1 elicited parasite-and antigen-specific IgM and IgG (IgG2.IgG1) responses. Upon challenge
infection, TcVac1-vaccinated dogs, as compared to non-vaccinated controls dogs, responded to T. cruzi with a rapid
expansion of antibody response, moderately enhanced CD8
+ T cell proliferation and IFN-c production, and suppression of
phagocytes’ activity evidenced by decreased myeloperoxidase and nitrite levels. Subsequently, vaccinated dogs controlled
the acute parasitemia by day 37 pi (44 dpi in non-vaccinated dogs), and exhibited a moderate decline in infectivity to
triatomines. TcVac1-immunized dogs did not control the myocardial parasite burden and electrocardiographic and
histopatholgic cardiac alterations that are the hallmarks of acute Chagas disease. During the chronic stage, TcVac1-
vaccinated dogs exhibited a moderate decline in cardiac alterations determined by EKG and anatomo-/histo-pathological
analysis while chronically-infected/non-vaccinated dogs continued to exhibit severe EKG alterations.
Conclusions: Overall, these results demonstrated that TcVac1 provided a partial resistance to T. cruzi infection and Chagas
disease, and provide an impetus to improve the vaccination strategy against Chagas disease.
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Introduction
American trypanosomiasis (Chagas disease) is a disease of
humans and caused by the protozoan Trypanosoma cruzi of the
family trypanosomatidae [1]. Approximately 30–40% of the
infected patients develop a chronic debilitating illness of the
cardiac system, characterized by clinically irreversible and
progressive tissue destruction, and myocardial hypertrophy,
eventually leading to heart failure and the patient’s death [2,3].
Several investigators have shown the potential utility of T. cruzi
surface antigens as vaccine candidates in murine experimental
models [4,5](reviewed in [6,7]). We have shown the protective
efficacy of amastigote surface proteins ASP-1 and ASP-2, and
trypomastigote surface antigen TSA-1 as DNA vaccines in mice
[8]. Vaccination with ASP-2 provided maximal immunity to T.
cruzi infection in mice that was further enhanced by co-delivery of
cytokine adjuvants [8]. In recent studies, we have identified
additional potential vaccine candidates by computational screen-
ing of T. cruzi sequence database [9]. Of these, TcG1-TcG8 were
phylogenetically conserved in clinically important strains of T. cruzi
and expressed in the infective and intracellular stages of the
parasite [9]. When delivered as a DNA vaccine in mice, TcG1,
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response and Th1 cytokine (IFN-c) response, a property associated
with immune control of T. cruzi [10]. These novel vaccine
candidates, thus, increased the pool of protective vaccine
candidates against T. cruzi.
In this study, we proceeded to examine the prophylactic and
transmission-blocking efficacy of the multi-component vaccine
constituted of TcG1, TcG2 and TcG4 in dogs. We chose dogs for
our studies because dogs provide an excellent model for studying
the human disease [11–13]. Experimentally and naturally infected
young dogs (2–3 months) elicit reproducible and comparable acute
infection associated with increase in blood parasitemia, IgG and
IgM antibodies [14,15] and T cell response [16]. The presence of
myocarditis with a moderate or small number of parasitized cells
and extensive and frequent focal necrosis turns the disease in dogs
similar to acute Chagas disease in humans [17,18]. A few infected
dogs (10–20%; 5% humans) develop severe acute myocarditis and
may die of cardiac arrest. More than 80% of dogs recover from
acute parasitemia as parasites become undetectable in the blood,
and remnant mild myocardial changes with scattered microscopic
foci of fibrosis and lymphocytic infiltration [19] present a picture
similar to that of human infections [20,21]. At 12–18 months post-
infection (pi), ,50% of infected dogs exhibit symptomatic chronic
cardiac disease (20% develop severe myocarditis), associated with
progressive cardiomegaly; arrhythmia, including RBBB with left
anterior hemiblock [22,23]; diffused myocarditis with focal and
interstitial fibrosis, and self-perpetuating myofibril destruction - a
picture reminiscent of the chronic form of Chagas disease
observed in humans. Thus, testing the vaccine efficacy in dogs
would provide a strong basis for developing a human vaccine
against T. cruzi and Chagas disease.
Further, dogs are an important reservoir host for domestic
transmission of T. cruzi. The prevalence rate of T. cruzi infection in
dogs may reach up to 84% in endemic areas (e.g. rural Argentina,
Chiapas, Mexico), determined by serological procedures and
xenodiagnosis [24,25]. Dogs are also the most frequent blood meal
source for the domestic triatomines, i.e., T. barberi and T.
pallidipennis in Mexico [15] and T. infestans in Argentina [25,26].
Likewise, a high prevalence of seropositive dogs and infected
triatomines is routinely noted in rural and urban development in
the southern US [27,28], and suggested to maintain T. cruzi
transmission in the human habitat. Triatomines are several times
more likely to take their blood meal from dogs than from humans
[26]. The ratio of dog blood meals to human blood meals in the
engorged guts of triatomines is estimated to be 2.3–2.6 times
higher than the ratio of the number of dogs to the number of
humans in a household [29]. Thus, the probability of infecting an
insect in one blood meal from dogs is estimated to be 200-times
higher as compared to the probability from adult humans [25].
These studies demonstrate that dogs are an important host blood
source for domiciliary triatomines, and the risk of T. cruzi infection
in humans is increased by the presence of infected dogs. Strategies
that can limit T. cruzi infection in domestic reservoir host may,
thus, prove to be effective in interrupting the parasite transmission
to the vector, and consequently, to the human host.
We immunized dogs with DNA-prime/DNA-boost vaccine
(TcVac1). We examined the efficacy of TcVac1 in eliciting
antigen-and parasite-specific antibody and T cell immunity, and
determined if vaccination with TcVac1 modulated the host
immune response towards protective type 1 upon T. cruzi infection.
We also examined the efficacy of TcVac1 in controlling acute
parasitemia, blocking the parasite transmission to triatomines, and
preventing clinical severity of chronic disease.
Materials and Methods
Animals
Twelve mongrel dogs (6 males and 6 females, 3–4 months old)
were acquired locally and kept at the animal facility at the UAEM
Research Center until they were included in the experiment, at
eight months of age (8–12 kg body weight). Dogs were confirmed
free of T. cruzi infection by microscopic examination of blood
smears and serological evaluation of anti-T. cruzi antibodies using
an indirect haemagglutination assay (IHA) and enzyme-linked
immunosorbent assay (ELISA) [15,18]. Before inclusion in
experimental studies, dogs were treated with anti-helminthes and
vaccines against regional infectious diseases (Canine distemper,
Parvovirus infection, Canine hepatitis, Leptospirosis, and Rabies).
All dogs received water ad libitum, and commercial dog food fed
twice a day according to their age and development requirements.
Experimental protocols were conducted under the technical
specifications for the production, care, and use of lab animals
from the Norma Official Mexicana (NOM-062-ZOO-1999), and
the Council for International Organizations of Medical Science
[30,31]. The research protocols were approved by the Laboratory
Animal Care Committee at the Universidad Nacional Autonoma
de Mexico.
Immunization and challenge infection
TcVac1 vaccine was constituted of antigen-encoding plasmids
(pCDNA3.TcG1, pCDNA3.TcG2 and pCDNA3.TcG4) and IL-
12- and GMCSF-expression plasmids, described previously [8,32].
The eukaryotic expression plasmids encoding dog cytokines (IL-12
and GM-CSF) were a kind gift from Dr. Peter Melby [33]. All
recombinant plasmids were transformed into E. coli DH5-a
competent cells, grown in L-broth containing 100 mg/ml ampicil-
lin, and purified by anion exchange chromatography using the
Qiagen maxi prep kit (Qiagen, Chatsworth, CA) according to the
manufacturer’s specifications. Trypomastigotes of T. cruzi (Syl-
vioX10/4) were maintained and propagated by continuous in vitro
passage in C2C12 cells.
Dogs (n=6/group, 3 males and 3 females) were intramuscularly
immunized with TcVac1 (200 mg each plasmid DNA/dog),
delivered four-times at 2-week intervals. Dogs vaccinated with
empty vector (pcDNA3 only) were used as controls. Two-weeks
after the last immunization, dogs were challenged with culture-
derived T. cruzi SylvioX10/4 (3.5610
3 trypomastigotes/kg body
weight, i.p.). The selected dose of the parasites was sufficient to
produce acute parasitemia within 1–2 weeks of inoculation, and
symptomatic clinical disease within 6–8 weeks post-infection [18].
Dogs were observed daily for general physical condition, at weekly
intervals for clinical condition, and at 2-week intervals for cardiac
function, monitored by electrocardiography (EKG). Sera samples
were obtained before each immunization and at two-week
intervals thereafter. After challenge infection, in addition to sera
Author Summary
Immunization of dogs with DNA-prime/DNA-boost vaccine
(TcVac1) enhanced the Trypanosoma cruzi-specific type 1
antibody and CD8
+ T cell responses that resulted in an
early control of acute parasitemia and a moderate decline
in pathological symptoms during chronic phase. Further
improvement of vaccine-induced immunity would be
required to achieve clinical and epidemiological benefits
and prevent transmission of parasites from vaccinated/
infected dogs to triatomines.
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beginning day 5 pi, on alternate days up to 50 dpi and at two-week
intervals thereafter.
Parasitological measures
We measured blood parasitemia using hemacytometer counts of
5 ml blood mixed with equal volume of ACK red blood cell lysis
buffer. Xenodiagnostic analysis was performed as described
[25,34,35]. Briefly, stage 4 naive triatomine (T. pallidipenis) nymphs
(6 per dog) were fed on vaccinated and control dogs on day 30 and
day 60 pi. Fecal samples were collected from triatomines at day 60
after feeding, and analyzed by light microscopy to detect
epimastigote and metacyclic trypomastigotes. At least 10 micro-
scopic fields were analyzed for each fecal sample, and triatomines
were considered T. cruzi positive when .1 parasites were detected.
Serology
The cDNAs for TcG1, TcG2 and TcG4 were cloned in pET-22b
plasmid (Novagen) such that the encoded proteins would be
expressed in-frame with a C-terminal His-tag. All cloned
sequences were confirmed by restriction digestion and sequencing
at the Recombinant DNA Core Facility at UTMB. For the
purification of recombinant proteins, plasmids were transformed
in BL21 (DE3) pLysS competent cells, and recombinant proteins
purified using the polyhistidine fusion peptide-metal chelation
chromatography system (Novagen).
Blood samples were obtained by venopuncture of the cephalic
vein, and immediately processed to separate sera, using standard
methods [15,18]. Sera samples (1:50–1:100 dilution) were
analyzed for IgM and IgG by using the Chagas diagnostic kits
for ELISA (Laboratorio-Lemos SRL, Buenos Aires, Argentina).
The horseradish peroxidase (HRP)-labeled anti-human-IgG in
ELISA kit was replaced with HRP-conjugated goat-anti-dog IgM-
or IgG-specific secondary antibody (Bethyl Laboratories) [15,18].
In some experiments, instead of T. cruzi lysate, plates were coated
with recombinant antigens (TcG1, TcG2 or TcG4, 10-mg protein/
ml) to capture the antigen-specific antibodies. Sera samples from
chronically infected dogs with confirmed T. cruzi infection and
from healthy domestic dogs were used as positive and negative
controls, respectively (cut off value: ELISA, mean OD450nm from
negative dogs 62 SD; IHA, positive titer at $1:16 serum dilution).
To identify the antibody sub-types (IgG1 and IgG2), plates were
coated with T. cruzi antigen, and, then sequentially incubated at
room temperature with sera samples (1:50 dilution) for 2 h, biotin-
conjugated goat anti-dog Ig subtypes (IgG1 and IgG2) for 2 h, and
streptavidin-horseradish peroxidase conjugate for 30 min. All
antibodies and conjugates were from Bethyl Laboratories, and
used at a 1:3000 dilution in PBST-0.5% NFDM (100-ml/well).
Color was developed with 100-ml/well Sure Blue TMB substrate
(Kirkegaard & Perry Labs), reaction was stopped with 2N sulfuric
acid, and antibody response was monitored at 450 nm using a
SpectraMax M5 microplate reader.
Spleen cell phenotype
Splenic level of CD4
+ and CD8
+ cell population in immunized/
challenged dogs was determined by flow cytometry. Briefly,
splenocytes were suspended in PBS (1610
6 cells/100 ml) and
incubated for 30 min with FITC-conjugated anti-CD4 and PE-
conjugated anti-CD8 antibodies (1:50 dilution, from ABD
Serotec). Following incubation, cells were fixed with 2%
paraformaldehyde, washed and re-suspended in 500 ml PBS, and
analyzed on a FACScan apparatus (BD Biosciences). Cells stained
with PE- and FITC- conjugated rat IgGs (isotype matched) were
used as negative controls. Flow data were analyzed by Cell Quest
software (BD Biosciences).
Serum cytokine levels
Cytokine levels in sera of vaccinated dogs were measured by
sandwich ELISA. Briefly, 96 well plates were coated overnight
with anti-IFN-c or anti-IL-10 antibodies (500-ng/ml in PBS),
washed with PBS/0.05% Tween-20 (PBST), and incubated for
2 h with 1% BSA. Plates were then sequentially incubated at room
temperature with sera samples (50-ml/well) for 2 h, biotinylated
anti-dog IFN-c antibody (0.5-mg/ml) or anti-dog IL-10 antibody
(2-mg/ml) for 2 h, and streptavidin conjugated horse radish
peroxidase (1:3000 dilution) for 45 min. All antibodies were from
R&D systems. Colorimetric reaction was performed as above.
Cytokine concentrations were calculated using a standard curve
derived using recombinant IFN-c or IL-10 (1–4000 pg/ml).
Myeloperoxidase (MPO) activity
MPO activity was determined by a dianisidine-H2O2 method
[36], modified for 96-well plates [37]. Briefly, plasma samples (10-mg
protein) were added in triplicate to 0.53 mM o-dianisidine
dihydrochloride (Sigma) and 0.15 mM H2O2 in 50 mM potassium
phosphate buffer (pH 6.0). After incubation for 5 min at room
temperature, the reaction was stopped with 30% sodium azide
and the change in absorbance was measured at 460 nm
(e=11,300 M
21 cm
21). Results were expressed as units of
MPO/mg protein, whereby one unit of MPO was defined as the
amount of enzyme degrading one n mol H2O2 per min at 25uC.
Nitrite level
The nitrite/nitrate content, indicative of inducible nitrite oxide
synthase (iNOS) activity, was monitored by the Greiss reagent
assay, as described [37]. In 96-well plates, reduced plasma samples
(10 mg protein) were mixed with 100 ml Greiss reagent, consisting
of 1% sulfanilamide in 5% phosphoric acid and 0.1% N-(1-
napthyl)ethylenediamine dihydrochloride (1:1, v/v), and incubated
for 10 min. The change in absorbance was monitored at 545 nm
(standard curve, 0–200 n mol sodium nitrite).
Electrocardiography
Changes in cardiac rhythm and conduction in all dogs was
monitored before inclusion in the study, and after challenge
infection, at 2-week intervals up to 8-weeks and at monthly
intervals thereafter. We used electrocardiograph (Stylus, EK-8,
USA) setting at 120 V, 60 Hertz, 20 amps, and 25 Watt in all
experiments. Six leads of the electrocardiogram were considered at
25 mm/sec at 1-mV, standardized to 1 cm for the present study.
Necropsy and histological studies
Necropsy was performed the day animals died due to infection
or after humanitarian sacrifice at day 60 (acute phase) and day 365
(chronic phase) post challenge infection. Dogs were sedated with
xylazine (1–3 mg/kg body weight) and then euthanized according
to the Mexican Norma Official Mexicana [30,31], using protocols
approved by the Laboratory Animal Care Committee at the
Universidad Nacional Autonoma de Mexico. A macroscopic and
microscopic analysis of affected organs was performed. Postmor-
tem studies were conducted using standard protocols with
emphasis on macroscopic findings related to Chagas disease in
heart tissue [15]. For histological analysis, tissue samples were
fixed in 10% buffered formalin for 24 h, dehydrated in absolute
ethanol, cleared in xylene, and embedded in paraffin. Tissue
sections (5-mm thick) were stained with hematoxylin-eosin, and
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were scored 0 to 4 in blind studies, according to the extent of
inflammation and tissue damage from normal to total wall
involvement [38].
Statistical analysis
Data are expressed as means 6 SD, and derived from duplicate
experiments (n$6 animals/group/experiment) with at least
duplicate observations per sample. Results were analyzed for
significant differences using ANOVA procedures and Student’s
t-tests. The level of significance was accepted at *p,0.05
(vaccinated versus non-vaccinated).
Results
The development of an antibody response induced by TcVac1
was determined by an ELISA. All dogs were seronegative before
vaccination was initiated. The T. cruzi-specific IgM and IgG
antibody response was detectable in sera (1:50 dilution) of
vaccinated dogs after the first immunization, and moderately
increased upon delivery of booster vaccine doses (Fig. 1A&B). The
level of antigen-specific antibody response was detected in the
order of TcG1.TcG2.TcG4, and was additive in nature
(Fig. 1E). The vaccine-induced antibody response was predomi-
nantly of the Th1 type with IgG2/IgG1 ratios .1 (Fig. 1C&D).
Figure 1. TcVac1-induced antibody response in dogs. Dogs were vaccinated with TcVac1 or injected with vector only, and sera were collected
two weeks after each immunization dose. An ELISA was performed to monitor the sera levels (1:50 dilution) of parasite-specific IgM (A), IgG (B), IgG1
(C) and IgG2 (D). The vaccine-induced antigen-specific (TcG1, TcG2 and TcG4) antibody response in sera collected 14 days after last dose of vaccine
was determined using recombinant antigens. Data are presented as mean 6 SD (*p,0.05, vaccinated versus non-vaccinated, n=6 per experiment).
doi:10.1371/journal.pntd.0001050.g001
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parasite- and antigen-specific antibody response (Fig. 1).
After challenge infection with T. cruzi, sera samples were
analyzed at 2-week intervals (1:100 dilution) (Fig. 2). Non-
vaccinated/infected dogs exhibited a slight increase in parasite-
specific IgM levels (Fig. 2A). All dogs, irrespective of vaccination
status, responded to T. cruzi infection by a gradual increase in anti-
parasite IgG levels (Fig. 2B). The TcVac1-immunized dogs
exhibited a faster increase in IgG antibody response to T. cruzi
infection (Fig. 2B, p,0.05) as compared to that detected in non-
vaccinated/infected dogs. Likewise, the vaccine-induced domi-
nance of IgG2 antibodies (compared to IgG1 subtype) was
significantly expanded after infection (Fig. 2C&D). Together, the
results presented in Fig. 1 and Fig. 2 suggested that vaccination of
dogs with TcVac1 skewed the antibody response towards Th1 type
that was further expanded upon challenge infection with T. cruzi.
Next, we measured vaccine’s efficacy in activation of phagocytic
(neutrophils and macrophages) response to T. cruzi by evaluating
the plasma level of MPO activity and nitrite contents (Fig. 3).
Vaccinated and non-vaccinated dogs exhibited no detectable level
of MPO activity before challenge infection (Fig. 3A). After
exposure to T. cruzi, all dogs responded by a rise in MPO activity.
During day 15–30 pi, non-vaccinated/infected and vaccinated/
infected dogs exhibited a 2-fold and 25% increase in MPO activity
in response to T. cruzi infection (Fig. 3A). After day 30 pi, all dogs
exhibited a similar decline in circulatory MPO activity. Likewise,
the nitrite levels, indicative of iNOS activation and NO
production, were increased by 2-fold in non-vaccinated/infected
dogs at 30 dpi, while vaccinated/infected dogs exhibited ,22%
increase in plasma nitrite contents (Fig. 3B). These data suggested
that immunization with TcVac1 suppressed the T. cruzi-mediated
activation of phagocytes evidenced by decreased plasma levels of
Figure 2. The antibody response to T. cruzi infection was polarized to type 1 in vaccinated dogs. Dogs were vaccinated as above, and
infected with T. cruzi. An ELISA was performed to evaluate sera levels (1:100-dilution) of T. cruzi-specific IgM (A), IgG (B), IgG1 (C), and IgG2 (D)
antibodies at 0, 15, 30, 45, and 60 days post-infection.
doi:10.1371/journal.pntd.0001050.g002
Figure 3. Shown are plasma levels of myeloperoxidase activity
(A) and nitrite content (B) in dogs immunized with vector only
or TcVac1 vaccine during the course of 0–60 days post-
infection. Data are presented as mean 6 SD (*p,0.05).
doi:10.1371/journal.pntd.0001050.g003
TcVac1 Efficacy against Trypanosoma cruzi in Dogs
www.plosntds.org 5 May 2011 | Volume 5 | Issue 5 | e1050MPO and nitrite in vaccinated/acutely-infected dogs as compared
to non-vaccinated controls.
A predominance of CD8
+ T cells and type 1 cytokines (IFN-c)i s
shown to be essential for control of T. cruzi infection [32]. All dogs,
irrespective of vaccination regimen, responded to T. cruzi infection
by a strong increase in parasite-specific lymphocyte activation
(Fig. 4). The vaccinated/infected dogs exhibited a moderately
stronger CD8
+T cell response as compared to the non-vaccinated/
infected dogs that was maintained during acute infection and
chronic disease phase (Fig. 4A). The circulatory cytokine levels
(IFN-c and IL-10) were below detection limit before and after
immunization with TcVac1. The sera level of IL-10 remained
undetectable after challenge infection with T. cruzi in all dogs. In
comparison, all dogs responded to infection by a rapid increase in
circulatory IFN-c level that was significantly higher in vaccinated/
infected dogs as compared to that noted in non-vaccinated/
infected dogs (Fig. 4B). These results indicated that TcVac1-
immunized dogs were moderately better than non-vaccinated dogs
in responding to T. cruzi infection by elicitation of higher level of
type 1 biased CD8
+T cell response.
Detectable parasitemia that peaked during day 30–35 pi was
noted in all dogs (Fig. 5A). Dogs vaccinated with TcVac1 exhibited
an early rise in parasitemia that was controlled by day 37 pi. In
comparison, non-vaccinated/infected dogs exhibited a slight delay
in peak parasitemia; however, blood parasitemia persisted beyond
day 37 pi. No signs of clinical illness were apparent in vaccinated/
infected and non-vaccinated/infected dogs during the physical
exam, yet 33% of the TcVac1-vaccinated/infected dogs suc-
cumbed during 40–42 dpi (Fig. 5B).
Xenodiagnostic studies were performed to determine if dog’s
infectivity to triatomines is altered by vaccination.Triatomines were
fed on dogs during acute phase (30 dpi) and after control of acute
parasitemia (60 dpi), and feces were analyzed 30 days post-feeding
for the detection of parasites by microscopy. In agreement with the
peak parasitemia, all triatomines fed at day 30 pi on vaccinated and
non-vaccinated dogs became T. cruzi positive. Of the 36 triatomines
fedon eachgroup ofdogsatday60pi, 47% (17out of36)insects fed
on TcVac1-vaccinated/infected dogs and 30% (11 out of 36) insects
fed on non-vaccinated/infected dogs died during the incubation
period. Of those surviving, we detected T. cruzi in feces of 52.63%
(10/19) and 84.6% (21/25) of the insects fed on vaccinated/infected
and non-vaccinate/infected dogs, respectively. These results
indicated that TcVac1 was not effective in preventing infection or
early rise in acute parasitemia, and was moderately effective in
reducing the time-course of parasitemia and dogs’ infectivity to
triatomines after day 37 post-infection.
Normal electrocardiographic readings were noted in all dogs
included in the study, before and after immunization. After
challenge infection, vaccinated/infected and non-vaccinated/
infected dogs exhibited no cardiac alterations up to 30 dpi. By
day 60 pi, 67% of non-vaccinated dogs displayed electrocardio-
graphic alterations, including reduced P-R interval, reduced R
wave voltage, axis rotated to the right, S-T segment line elevation
from the isoelectric line (.0.2 mV), long QT segment, J wave
elevation, and sinus tachycardia that were diagnostic of myocar-
ditis, pericarditis, and high degree of myocardiocyte necrosis. Two
vaccinated/infected dogs died by day 42 pi due to high electrical
conductance problems and arrhythmia. Of remaining, 50% of the
vaccinated/infected dogs exhibited at 60 dpi no electrocardio-
graphic alterations, and other 50% exhibited a moderate level of
EKG abnormalities including low voltage complex, a positive
deviation of S-T with elevation of J-wave, left axel rotation, and
tachycardia that were diagnostic of ventricular dilation, myocar-
ditis, and arrhythmia. At one-year post-challenge infection,
electrocardiographic analysis revealed a spectrum of cardiac
dysfunction in chronically infected dogs. Among the unvaccinat-
ed/chronically-infected dogs, 66% exhibited major electrical
conduction problems (right axel rotation and LBBB), and 33%
exhibited lateral re-polarization problems. Among the vaccinated/
chronically-infected dogs, 33% exhibited electrical conduction
problems (right axel rotation and LBBB) similar to that noted in
unvaccinated/infected dogs, 33% showed minor axel rotation
problems, and 33% dogs exhibited normal EKG. On a scale of 0
(normal) to 10 (severe EKG alterations), 66% of non-vaccinated/
chronically infected dogs were graded as 10 and 33% as normal
(zero EKG alterations). In comparison, 33% of vaccinated/
chronically infected dogs were graded normal (0), 33% moderate
(score: 5), and 33% with severe electrical conduction problems
(score: 10) at one year post-infection.
Next, we evaluated the pathology of the heart in dogs.
Anatomo-pathological analysis of the heart, performed at day 60
pi, showed dilated cardiomyopathy (bi-ventricular dilation) and
focal and diffused myocarditis in vaccinated dogs as well as in dogs
injected with vector alone (Fig. 6). Irrespective of vaccination
status, some animals exhibited whitish zones and rounded edges in
the spleen, dilation of esophagus, and pinkish ampoules at the
cecum. At one-year post-challenge infection, all dogs had round
shaped hearts. Sixty six percent of non-vaccinated/chronically
infected dogs exhibited severe right ventricle dilation. In
comparison, 66% of vaccinated/chronically-infected dogs exhib-
ited moderate level of right ventricle dilation. Epicardial
hemorrhages were seen in 66% dogs from the control group and
33% dogs in the TcVac1 group.
Figure 4. T cell and cytokine response in vaccinated dogs.
(A) Spleen cells were obtained from vaccinated and non-vaccinated
dogs at one year after challenge infection with T. cruzi. Spleen cells
were incubated for 30 min with FITC-conjugated anti-CD8 and PE-
conjugated anti-CD4 antibodies and CD4
+ and CD8
+ T cell subsets
monitored by flow cytometry. (B) The circulatory IFN-c level was
measured by an ELISA. Data are presented as mean 6 SD (*p,0.05).
doi:10.1371/journal.pntd.0001050.g004
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differences between two groups (Fig. 7). In epicardium of dogs
vaccinated with TcVac1, non-suppurative moderate to severe
myocarditis with focal or zonal mononuclear and polymorphonu-
clear inflammatory infiltrate associated with presence of amasti-
gotes nests and severe active necrosis was generally noted. In non-
vaccinated/infected dogs, histopathological findings were similar
to that noted in vaccinated dogs with the exception that
inflammatory infiltrate tended to be mainly constituted of
mononuclear rather than polymorphonuclear cell type (Fig. 7).
In the myocardium, vaccinated and non-vaccinated dogs exhibited
multiple coagulative necrosis foci with mononuclear infiltration
and some necrotic areas with polymorphonuclear and neutrophil
infiltration. The diffused multi-focal and zonal mononuclear
inflammatory infiltrate and hemorrhagic areas in myocardium
appeared to be larger in vaccinated/infected dogs (Fig. 7C, C2) as
compared to non-vaccinated/infected dogs (Fig. 7B, B2). Vacci-
nated/infected dogs also showed abundant cellular detritus in
myocardium. Mononuclear infiltration was moderate in ventricles
and septum of all dogs. Folding of myocardial fibers in right
ventricle was observed in both vaccinated/acutely-infected and
non-vaccinated/acutely-infected dogs. Mural multifocal endocar-
ditis with mononuclear infiltration was also noted in dogs from the
two groups. Abundant amastigote nests (range 18–21 per
microscopic field (mf)) were found in each region (right and left
ventricles, and septum) of the heart of TcVac1-vaccinated/
acutely-infected dogs. Non-vaccinated/infected dogs exhibited,
in general, lesser number of parasite foci in equivalent studied
areas. Statistical analysis showed that overall, the number of
myocardial necrotic foci, lymphocyte infiltration foci and number
of amastigote nests were more abundant in TcVac1-vaccinated
dogs than was observed in non-vaccinated/infected dogs at 60 dpi
(p,0.05) (Fig. 7).
At one-year post-challenge infection, severe myocardial inflam-
mation persisted in 66% of the non-vaccinated/infected dogs
while remaining 33% exhibited slight inflammatory infiltrate in
Figure 5. (A Data are presented as mean 6 SD (*p,0.05). (B) Percent survival from
infection.
doi:10.1371/journal.pntd.0001050.g005
Figure 6. Morphological alterations in the heart. Dogs were vaccinated and infected with T. cruzi as above. Shown are representative
morphologic alterations of the heart during the acute infection phase (60 dpi) in dogs injected with vector only (B&B1) or immunized with TcVac1
(C&C1). Images of normal heart (A&A1) are shown for comparison. Horizontal arrows show right ventricle wall thinning characteristic of ventricle
dilation. Vertical arrows show pale striated epicardium and myocardium, characteristic of necrosis produced after inflammatory response to infection.
doi:10.1371/journal.pntd.0001050.g006
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Blood parasitemia was  ) determined by light microscopy   . the heart. In comparison, 66% of vaccinated/chronically infected
dogs exhibited moderate level of myocardial inflammatory
infiltrate. Slight to moderate presence of connective tissue was
apparent in all chronically infected dogs; however, it was more
evident in TcVac1-vaccinated/chronic dogs. Folding of myocar-
dial fibers and vacuolization of Purkinje fibers was observed in
33% of vaccinated/chronically infected dogs.
Discussion
The objective of the present study was to test the efficacy of a
multi-component DNA vaccine (TcVac1) in dogs. The antigenic
candidates included in TcVac1 were identified by computational
analysis of T. cruzi sequence database and selected because they
were conserved among several clinically relevant T. cruzi strains,
expressed in infective and intracellular stages of T. cruzi [9], and
recognized by the antibody and T cell response in infected mice
[32] and humans (unpublished data). When delivered as a DNA
vaccine in mice, TcG1, TcG2 and TcG4 elicited trypanolytic
antibody response and Th1 cytokines (e.g. IFN-c) [9] that resulted
in significant protection from acute infection and chronic disease
severity. We utilized IL-12 and GM-CSF expression plasmids as
adjuvants as these cytokines induce type 1 B and T cell responses
[33], and shown to significantly enhance the protective immunity
elicited by the vaccine candidates in mice [8,39] and dogs [33]. To
the best of our knowledge, this is the first report testing the
prophylactic and transmission-blocking efficacy of DNA vaccine
against T. cruzi in dogs.
Immunization of dogs with TcVac1 resulted in elicitation of
antigen-specific and parasite-specific antibody response that was
dominated by IgG2 subtype. The delivery of booster doses of
vaccine resulted in no significant increase in antibody response
that could be explained, at least partially, by the fact that DNA
delivery system, used in this study, is known to drive a low level of
antigen expression. Several investigators have reported that needle
delivery of DNA vaccines in muscle induce low immune response
in large animals and humans, even when 1000-fold higher doses of
DNA than those proved to be effective in rodents were given
[40,41]. Other DNA vaccine delivery systems such as gene gun
(biolistic gun) [42,43], adenovirus or vaccinia virus delivery vectors
[44], replicating attenuated strains of intracellular microorgan-
isms, such as Salmonella [45] have shown promising results in
eliciting antigen expression. Additionally, heterologous prime/
boost approaches are noted to be more effective in eliciting
stronger, long-term immunity against intracellular pathogens
[46,47], to be tested in future studies.
Despite low vaccine-induced antibody response, vaccinated
dogs, upon challenge infection with T. cruzi, exhibited an early
expansion in antibody response. The Ig (G+M) response during
acute phase was of higher magnitude in vaccinated/infected dogs
than that observed in dogs injected with vector alone. The IgG
response in vaccinated/infected dogs was primarily of the Th1
type with IgG2/IgG1 ratios being .1, known to provide
protection from acute infection in dogs [48,49]. The higher level
and rapid expansion of antibody titers indicates that TcVac1
primed the B cell response that was expanded upon exposure to T.
cruzi. Previously, we have shown that TcG1-, TcG2- and TcG4-
specific antibodies, elicited in vaccinated mice, were lytic in
nature, and efficiently killed trypomastigotes in a complement-
dependent manner [9]. In this study, our observation of a shorter
detectable parasitemic period of 37 days in vaccinated/infected
dogs than that noted in control dogs (44 days) indicate that
antibody response primed by vaccination with TcVac1 was lytic in
nature and contributed to a control of blood parasitemia. Yet,
immunization with TcVac1 failed to prevent peak parasitemia.
This was likely because other components of immune system, i.e.,
innate response constituted by phagocytes and type 1 biased CD8
+
T cell response, were not strongly primed by vaccine or expanded
upon challenge infection in vaccinated dogs. It is well documented
that phagocytes, through activation of NADPH oxidase, MPO,
and iNOS activities and production of cytotoxic reactive oxygen
and nitrogen species, play an important role in control of T. cruzi
[37,50-52]. Numerous studies have also demonstrated that an
efficient control of acute parasitemia requires concerted activities
of Th1 helper cells, and cytotoxic CD8
+ T lymphocytes (CTLs)
(reviewed in [53,54]). Vaccination with TcVac1 resulted in a
suppression of phagocytes’ response to challenge infection as was
evidenced by decreased activation of MPO and iNOS activity in
vaccinated/infected dogs as compared to that noted in non-
vaccinated/acutely infected dogs. Equally, immunization with
TcVac1 resulted in a significant but only moderately better
expansion of CD8
+ T cells and IFN-c levels upon challenge
infection when compared to that noted in non-vaccinated/infected
dogs. Consequently, it was not surprising to find no significant
decline in infectivity of vaccinated dogs to triatomines during the
acute period of infection. All triatomines, fed on vaccinated/
infected or non-vaccinated/infected dogs when dogs were
exhibiting peak parasitemia (day 30 pi), and analyzed at day 60
post-feeding, were infected evidenced by fecal presence of T. cruzi.
However, at 60 dpi, vaccinated dogs exhibited a better control of
parasitemia and moderately reduced infectivity to triatomines
(52.63% versus 84.6% infected). The mathematical modeling of
transmission dynamics [55] and other studies using insecticide-
treated dog collars [56,57] indicate that a decline in infectivity to
,20% would be required to block vectorial transmission of T. cruzi
to humans. Thus, we surmise that current formulation of TcVac1,
though provided a decline in dogs’ infectivity to triatomines after
peak parasitemia, would not be effective in blocking the
Figure 7. Histological analysis of hearts. Dogs were vaccinated,
and challenged with T. cruzi. Heart tissue sections (5-ı `M) from left
ventricle, septum, and right ventricle were obtained at 60 days post-
infection (acute phase), and stained with hematoxylin-eosin. Shown are
representative micrographs of dogs injected with vector only (B,B1,B2)
or immunized with TcVac1 (C,C1,C2). Micrographs from normal/
uninfected dogs (A,A1,A2) are shown for comparison. Vertical arrows
show amastigote nests and horizontal arrows show lymphocyte
infiltration, and cardiomyocytes destruction.
doi:10.1371/journal.pntd.0001050.g007
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strategy is required.
Infection of dogs with SylvioX10/4 strain of T. cruzi produced
reproducible acute phase and chronic pathology as we have
previously reported [18], causing sudden death in some of the
infected dogs, and cardiomyopathic changes in most of the
infected animals during acute stage. EKG alterations were found
in more than half of the acutely infected dogs and ranged from
electrical conduction problems, ventricular dilatations, pericardi-
tis, myocarditis, high lateral necrosis, and arrhythmia. Most of
these changes were validated by necropsy and histopathology
findings, thus, confirming that this T. cruzi strain is highly
pathogenic in dogs. Despite a similar or higher infiltration of
inflammatory infiltrate in the heart, vaccinated dogs exhibited a
significantly higher number of amastigote nests (P,0.05) in
cardiac tissue than was observed in non-vaccinated control dogs
(Fig. 7). Others have reported a direct correlation between in vitro
infectivity and blood parasitism kinetics with heart parasitism
intensity during long-term infection of Beagle dogs [58,59].
Because of high inflammatory infiltrate and tissue parasite burden,
two of the vaccinated dogs exhibited myocarditis and died
suddenly due to arrhythmia.
Chronically infected/vaccinated dogs were better equipped in
controlling the disease symptoms. EKG findings demonstrated
mild-to-moderate cardiac alterations in animals given TcVac1
vaccine while severe EKG alterations persisted in dogs injected
with vector alone. These findings were supported by anatomo-
pathological analysis performed at one-year post-challenge
infection. Anatomo-pathological lesions and epicardial hemor-
rhages were fewer and moderate in TcVac1-vaccinated/chroni-
cally infected dogs as compared to non-vaccinated/chronic dogs
that exhibited severe right ventricle dilation and extensive
epicardial hemorrhages. These findings were observed despite
no decline in inflammatory infiltrate in the heart in chronically
infected dogs. These data indicate that TcVac1-induced immunity
was at least partially effective in controlling the clinical progression
of cardiac disease severity in chagasic dogs.
Summarizing, in this study, we tested a multi-component DNA
vaccine against T. cruzi infection in dogs. Our data showed that
TcVac1 geared a modest parasite- and antigen-specific type 1
antibody and CD8
+ T cell response that was effective in providing
an early control of acute parasitemia and moderately decreased
the infectivity of dogs to triatomines. However, tissue parasite
burden was not controlled in vaccinated dogs, likely due to
suppression of phagocytic cell response, evidenced by decreased
myeloperoxidase and nitrite (iNOS) levels in immunized dogs.
Despite this, vaccinated dogs exhibited a moderate decline in
cardiac alterations determined by EKG and anatomo-/histo-
pathological analysis during chronic stage of disease development.
Overall, our data demonstrated that TcVac1-elicited immunity
provided a partial protection from chronic Chagas disease and
provided an impetus to further improve the vaccination strategy
against Chagas disease.
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